SCHEMBL14917565

SCHEMBL14917565

C[C@H](Oc1ccc2ncccc2c1)c1nn(-c2cccc(Br)c2)ccc1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 1/20 0.42
MET P08581 3/20 0.41
SRC P12931 2/20 0.41
KDR P35968 2/20 0.41
AXL P30530 2/20 0.41
KIT P10721 1/20 0.41
FGFR2 P21802 1/20 0.41
FLT3 P36888 1/20 0.41
MST1R Q04912 1/20 0.41
NPC1 O15118 1/20 0.39
CASP3 P42574 1/20 0.39
RAB9A P51151 1/20 0.39
SENP8 Q96LD8 1/20 0.39
SENP7 Q9BQF6 1/20 0.39
SENP6 Q9GZR1 1/20 0.39
ALDH1A1 P00352 1/20 0.38
PDE4A P27815 2/20 0.36
KCNH2 Q12809 2/20 0.36
CYP3A4 P08684 1/20 0.36
PPARG P37231 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL360744 1.00 PDE10A (0.42) PDE10AMETSRCKDRAXL
SCHEMBL163738 0.80 PDE10A (0.44) PDE10ANPC1CASP3RAB9ASENP8
SCHEMBL367952 0.72 MEN1 (0.44) ALDH1A1HTTMEN1KMT2APOLB
SCHEMBL174256 0.72 CA12 (0.37) PDE10ANPC1CASP3RAB9ASENP8
SCHEMBL14916830 0.70 ALDH1A1 (0.40) METSRCKDRAXLKIT
SCHEMBL369191 0.69 PDE10A (0.37) PDE10ANPC1RAB9AALDH1A1CYP3A4
SCHEMBL10283802 0.68 PDE10A (0.44) PDE10ANPC1CASP3RAB9ASENP7
SCHEMBL360808 0.68 PDE10A (0.42) PDE10AKDRNPC1RAB9AALDH1A1
SCHEMBL14926826 0.67 KDM4E (0.42) PDE10ANPC1RAB9AALDH1A1CYP3A4
SCHEMBL827308 0.66 ALDH1A1 (0.61) METSRCKDRAXLKIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130116231-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2013-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116231-A1 TYROSINE KINASE INHIBITORS ABL1, ERBB2, MET PDE10A 3303/4885MET 3/4885SRC 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.